Introduction
- Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease of the nasal mucosa and sinuses that lasts at least 12 weeks.
- CRSwNP affects about 2–4% of people with symptoms such as smell loss, nasal obstruction, thick nasal drainage, and facial pressure.
- Some patients with CRSwNP also have comorbid asthma and develop acute respiratory reactions to nonsteroidal anti-inflammatory drugs (NSAIDs).
Table 1. Topical Steroids
Treatment
In people with CRSwNP, the Joint Task Force on Practice Parameters (JTFPP) suggests INCS rather than no INCS. ( C, L )
Additional considerations:
- The network meta-analysis linked to this guideline showed that delivery method of INCS was potentially important. INCS stent, spray, and EDS are among the most beneficial of the INCS delivery methods across multiple patient-important outcomes.
- The costs, availability, accessibility, and practical implications of the different methods of INCS delivery are likely to influence patient decision making.
- There is moderate certainty of evidence for the safety of INCS spray but safety may vary among the other delivery options. There is low or very low certainty in the safety of INCS using delivery methods other than spray.
- INCS have small treatment effect sizes. Patients with severe or rapidly recurrent disease may value more treatments with larger reductions in symptoms.
- There is probably uncertainty in the value and importance patients put on the outcomes that patients consider critical to decision making.
In people with CRSwNP, JTFPP suggests biologics rather than no biologics. ( C, M )
Additional considerations:
- For patients who have a symptom for which the improvement was considered to be important while receiving treatments other than biologics (i.e., INCS, surgery, or aspirin therapy after desensitization [ATAD]), not using biologics may be preferred.
- For patients using INCS for at least 4 weeks and who continue to have high disease burden, or for patients who have higher disease severity at presentation, biologics may be preferred over other medical treatment choices.
- There is variability in efficacy among the biologics and this may influence the overall choice. See Table 2 for more information.
- Patients who value not having the burden of payment and insurance approvals may be less likely to choose biologics. Patients who want to avoid the inconvenience of trialing potentially less effective medical therapies may prefer biologics.
- In aspirin exacerbated respiratory disease (AERD) specifically, biologics may be preferred over ATAD for patients who have increased risk of harms associated with daily aspirin therapy, or in patients who value the most efficacious therapies and/or patients who wish to avoid a strict daily oral medication regimen and its associated initial desensitization procedure.
- Patients with comorbid diseases that lead to a dual indication for biologic treatment may be a reason to choose biologics in general and even specific biologics.
In people with AERD, JTFPP suggests ATAD rather than no ATAD. ( C, M )
Additional considerations:
- Consider risks that impact the safety of performing an aspirin desensitization such as severe poorly controlled asthma. Consider risks that impact safety of long-term aspirin use such as conditions or treatments that increase bleeding risk.
- Biologics may be preferred over ATAD in AERD for patients who have increased risk of harms with ATAD or in patients who value the most efficacious therapies and/or avoiding a strict daily oral medication regimen and its associated desensitization procedure.
- Patients intolerant to NSAIDs and who require an NSAID for alternative indications may prefer ATAD over other options.
Table 2. Conditions Important for Shared Decision-Making
INCS - Delivery Method
Adverse effects: No diferent than placebo.
Additional issues: Spray is over the counter, and cost is not prohibitive to most.
Biologics
Adverse effects: Not diferent than placebo.
Additional issues: Very costly, needs long term treatment, no comparison with surgery and uncertain if it should be used with, before, or afer surgery. May be considered more favorably in those with other comorbidities that are treated with biologics.
Aspirin therapy after desensitization in patients with AERD
Clinical outcomes compared to placebo:
- Improves symptoms and quality of life
- Not different than placebo for smell
- May not decrease need for oral corticosteroids (OCS) or rescue surgery
Adverse effects:
- Bleeding risk and gastrointestinal (GI) side efects more common than placebo.
- Note: For every 10 people treated with ATAD, 1 will have an adverse sufficiently event enough to stop treatment.
Additional issues:
- Affordable, long term treatment
Table 3. Biologic Agents for CRSwNP
a Also indicated for atopic dermatitis, asthma, eosinophilic esophagitis and prurigo nodularis.
b Also indicated for eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.
c Also indicated for moderate to severe persistent asthma and chronic spontaneous urticaria (CSU).
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-Based Recommendations
Source: Grading of Recommendations Assessment, Development and Evaluation Working Group (Schunemann HJ et al. Am J Respir Crit Care Med. 2006;174:605-14. Guyatt GH et al. BMJ 2008;336:924-6).
Abbreviations
- AERD
- aspirin (nonsteroidal anti-inflammatory) -exacerbated respiratory disease
- ATAD
- aspirin therapy after desensitization
- CRSwNP
- chronic rhinosinusitis with nasal polyps
- CSU
- chronic spontaneous urticaria
- EDS
- exhalation delivery system
- GI
- gastrointestinal
- INCS
- intranasal corticosteroid
- JTFPP
- Joint Task Force on Practice Parameters
- NSAID
- nonsteroidal anti-inflammatory drug
- OCS
- oral corticosteroids
- QOL
- quality of life
Source Citation
Rank MA, Chu DK, Bognanni A, Oykhman P, Bernstein JA, Ellis AK, Golden DBK, Greenhawt M, Horner CC, Ledford DK, Lieberman J, Luong AU, Orlandi RR, Samant SA, Shaker MS, Soler ZM, Stevens WW, Stukus DR, Wang J, Peters AT, The Joint Task Force on Practice Parameters GRADE Guidelines for the Medical Management of Chronic Rhinosinusitis with Nasal Polyposis, Journal of Allergy and Clinical Immunology (2022), doi: https://doi.org/10.1016/j.jaci.2022.10.026.
Bognanni A, Chu DK, Rank MA, Bernstein J, Ellis AK, Golden D, Greenhawt M, Hagan JB, Horner CC, Ledford DK, Lieberman J, Luong AU, Marks LA, Orlandi RR, Samant SA, Shaker M, Soler ZM, Stevens WW, Stukus DR, Wang J, Peters AT. Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis. J Allergy Clin Immunol. 2022 Dec;150(6):1447-1459.
Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol. 2022 Apr;149(4):1286-1295.
Chu DK, Lee DS, Lee KM, Schunemann HJ, Szczeklik W, Lee JM. Benefits and harms of aspirin desensitization for aspirin exacerbated respiratory disease: a systematic review and meta-analysis. Int Forum Allergy Rhin. 2019;9:1409-19.
Expert Authors/Reviewers
Consultants:
Joint Task Force on Practice Parameters
Disclaimer
This resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers after consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary.
